surmount-osa tirzepatide results for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial Zepbound for Sleep Apnea: 2024

Are you aiming to reverse prediabetes

Therefore, these multifunctional DDSs serve not only as drug carriers but also as simple yet efficient nanoplatforms capable of performing additional theranostics functions

By leveraging the All of Us Research Program data, a nationally representative longitudinal health data from a diverse population, our findings provide new insights into the potential of GLP-1 RAs as a novel therapeutic strategy for addiction management and lay the groundwork for future clinical and translational research

Eder K, Felgner J, Becker K, Kluge H

10.1111/j.1463-1326.2008.01016.x 82

India Demonstrates Strong Market Potential with Rising Obesity Prevalence Revenue from obesity GLP-1 treatment in India is expanding at a CAGR of 28.4%, supported by increasing obesity rates in metropolitan areas and growing awareness of cardiovascular risk factors